Every earnings call for ONESOURCE — management tone, guidance, KPIs and promise tracking, quarter by quarter.
ONESOURCE · 6 transcripts · Healthcare · latest Q4 FY26Onesource Specialty Pharma Limited has 6 earnings calls on record here, a Healthcare company, most recently Q4 FY26. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.
Revenue 4282 million; EBITDA 919 million; Adjusted PAT 390 million. Revenue of INR 4,282 million, up 47% QoQ.
Read full transcript & analysisRevenue 2903 million (−26% YoY); EBITDA 173 million; Adjusted PAT -472 million. Revenue reported at ₹2,903 million, representing a 26% YoY decline due to semaglutide approval delays in Canada.
Read full transcript & analysisRevenue 2903 million (−26% YoY); EBITDA 173 million; Adjusted PAT -472 million. Reiterated FY28 guidance of $400 million revenue and $160 million EBITDA.
Read full transcript & analysisRevenue ₹327 cr (+12% YoY); EBITDA ₹88 cr (+37% YoY); EBITDA Margin 27%. Revenue reported at ₹327.3 crores, representing a 12% YoY growth.
Read full transcript & analysisRevenue 14449 million (+30% YoY); Operating EBITDA 4665 million (+100% YoY); EBITDA Margin 43%. Full year FY25 revenue exceeded ₹1,445 crores, representing 30% YoY growth.
Read full transcript & analysisRevenue ₹393 cr (+18% YoY); EBITDA ₹143 cr; EBITDA Margin 36.0%. Revenue for Q3 FY25 stood at ₹392.6 crores, representing approximately 18% growth.
Read full transcript & analysis